nach oben

Erschienen in:

01.04.2015 | Original article

HbA1c levels as predictors of ablation outcome in type 2 diabetes mellitus and paroxysmal atrial fibrillation

verfasst von: Z.-H. Lu, N. Liu, R. Bai, Y. Yao, S.-N. Li, R.-H. Yu, C.-H. Sang, R.-B. Tang, D.-Y. Long, X. Du, J.-Z. Dong, C.-S. Ma, MD, PhD

Erschienen in: Herz | Sonderheft 2/2015

Einloggen, um Zugang zu erhalten

Abstract

Aims

The aim of this study was to evaluate whether the levels of HbA1c could predict the outcome of ablation in patients with type 2 diabetes mellitus (T2DM) and paroxysmal atrial fibrillation (PAF).

Patients and methods

The study comprised 149 consecutive patients with T2DM and PAF who underwent their first circumferential pulmonary vein isolation. HbA1c levels were measured before ablation. Cox proportional hazards models were constructed to assess the relationship between HbA1c levels and the recurrence of atrial fibrillation (AF).

Results

Of the 149 patients, 60 (40.3 %) developed AF recurrence after a median 12-month follow-up. Multivariate Cox regression analysis revealed that left atrium size and HbA1c were independent predictors of recurrent atrial tachyarrhythmia. Receiver operating characteristic analysis demonstrated that an HbA1c cut-off value of ≥ 6.9 % predicted recurrence with 55.0 % sensitivity and 67.4 % specificity (AUC = 0.634). The success rate of ablation was 69.0 % in patients with an HbA1c value of < 6.9 % compared with 46.8 % in those with an HbA1c value of ≥ 6.9 % (log-rank test, p = 0.004).

Conclusion

High levels of HbA1c were associated with an increased risk of recurrence of atrial tachyarrhythmia in patients with T2DM and PAF undergoing catheter ablation.

Lip GY, Varughese GI (2005) Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. Int J Cardiol 105:319–321CrossRefPubMed

Huxley RR, Filion KB, Konety S, Alonso A (2011) Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation. Am J Cardiol 108(1):56–62CrossRefPubMedCentralPubMed

Forleo GB, Mantica M, De Luca L et al (2009) Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 20(1):22–28CrossRefPubMed

Joshi S, Choi AD, Kamath GS et al (2009) Prevalence, predictors, and prognosis of atrial fibrillation early after pulmonary vein isolation: findings from 3 months of continuous automatic ECG loop recordings. J Cardiovasc Electrophysiol 20(10):1089–1094CrossRefPubMed

o A (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352(9131):837–853CrossRef

Selvin E, Marinopoulos S, Berkenblit G et al (2004) Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421–431CrossRefPubMed

Iguchi Y, Kimura K, Shibazaki K et al (2012) HbA1c and atrial fibrillation: a cross-sectional study in Japan. Int J Cardiol 156(2):156–159CrossRefPubMed

American Diabetes Association (2010) Diagnosis and classification of diabetes mellitus. Diabetes Care 33:S62–S69CrossRef

Gage BF, Waterman AD, Shannon W et al (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285:2864–2870CrossRefPubMed

10.

Levy S, Maarek M, Coumel P et al (1999) Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 99:3028–3035CrossRefPubMed

11.

Du X, Ninomiya T, Galan B de et al (2009) Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 30:1128–1135CrossRefPubMed

12.

Santangeli P, Di Biase L, Al-Ahmad A et al (2012) Ablation as first-line therapy for atrial fibrillation: yes. Cardiac Electrophysiol Clin 4(3):287–297CrossRef

13.

Issa Z, Miller JM, Zipes DP (2012) Clinical arrhythmology and electrophysiology: a companion to Braunwald’s heart disease, 2nd edn. p 357

14.

Hare MJL, Shaw JE, Zimmet PZ (2012) Current controversies in the use of haemoglobin A1c. J Intern Med 271:227–236CrossRefPubMed

15.

American Diabetes Association (2010) Standards of medical care in diabetes. Diabetes Care 33:S11–S61CrossRef

16.

Huxley RR, Alonso A, Lopez FL, Filion KB et al (2012) Type 2 diabetes, glucose homeostasis and incident atrial fibrillation: the Atherosclerosis Risk in Communities study. Heart 98(2):133–138CrossRefPubMedCentralPubMed

17.

Chao TF, Suenari K, Chang SL et al (2010) Atrial substrate properties and outcome of catheter ablation in patients with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. Am J Cardiol 106:1615–1620CrossRefPubMed

18.

Lo LW, Tai CT, Lin YJ et al (2007) Progressive remodeling of the atrial substrate-a novel finding from consecutive voltage mapping in patients with recurrence of atrial fibrillation after catheter ablation. J Cardiovasc Electrophysiol 18:258–265CrossRefPubMed

19.

Vrhovac B et al (1997) Interna medicina, 2nd edn. Naprijed, Zagreb, pp 1365–1390

20.

Monnier L, Mas E, Ginet C et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295(14):1681–1687CrossRefPubMed

21.

Liu C, Fu H, Li J et al (2012) Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits. Anadolu Kardiyol Derg 12(7):543–550PubMed

22.

Basta G, Schmidt AM, De Caterina R (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63:582–592CrossRefPubMed

23.

Raposeiras-Roubín S, Rodiño-Janeiro BK, Grigorian-Shamagian L, Seoane-Blanco A et al (2012) Evidence for a role of advanced glycation end products in atrial fibrillation. Int J Cardiol 157(3):397–402CrossRefPubMed

24.

Van Heerebeek L, Hamdani N, Handoko ML et al (2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117:43–51CrossRef

25.

Kato T, Yamashita T, Sekiguchi A et al (2006) What are arrhythmogenic substrates in diabetic rat atria? J Cardiovasc Electrophysiol 17(8):890–894CrossRefPubMed

26.

o A (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977–986CrossRef

27.

Khaykin Y, Morillo CA, Skanes AC et al (2007) Cost comparison of catheter ablation and medical therapy in atrial fibrillation. J Cardiovasc Electrophysiol 18:907–913CrossRefPubMed

28.

Berruezo A, Tamborero D, Mont L et al (2007) Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J 28:836–841CrossRefPubMed

29.

Shigematsu Y, Norimatsu S, Ogimoto A et al (2009) The influence of insulin resistance and obesity on left atrial size in Japanese hypertensive patients. Hypertens Res 32:500–504CrossRefPubMed

Titel: HbA1c levels as predictors of ablation outcome in type 2 diabetes mellitus and paroxysmal atrial fibrillation
verfasst von: Z.-H. Lu
N. Liu
R. Bai
Y. Yao
S.-N. Li
R.-H. Yu
C.-H. Sang
R.-B. Tang
D.-Y. Long
X. Du
J.-Z. Dong
C.-S. Ma, MD, PhD
Publikationsdatum: 01.04.2015
Verlag: Urban & Vogel
Erschienen in: Herz / Ausgabe Sonderheft 2/2015
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-014-4154-6

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aims

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2015

Cancer antigen 125 levels and increased risk of new-onset atrial fibrillation

Outcome of cryoballoon ablation for atrial fibrillation

Association between MTHFR C677T polymorphism and congenital heart disease

Pseudoaneurysm of the mitral–aortic intervalvular fibrosa